Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Teduglutide
Drug ID BADD_D02137
Description Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Indications and Usage Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
Marketing Status approved
ATC Code A16AX08
DrugBank ID DB08900
KEGG ID D06053
MeSH ID C494910
PubChem ID 16139605
TTD Drug ID D00RCI
NDC Product Code 63557-1031; 68225-087; 68875-0101; 68875-0102; 69766-106; 68594-001; 41524-0009; 68875-0103; 17337-0264
UNII 7M19191IKG
Synonyms teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2
Chemical Information
Molecular Formula C164H252N44O55S
CAS Registry Number 197922-42-2
SMILES CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O )N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O) C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(= O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(C C(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C NC(=O)C(CC5=CN=CN5)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Cardiac failure congestive02.05.01.002---
Cholecystitis09.03.01.001--
Cholecystitis acute09.03.01.003---
Cholelithiasis09.03.01.002---
Cholestasis09.01.01.001---
Cough22.02.03.001--
Duodenal polyp07.20.01.008; 16.05.03.002---
Flatulence07.01.04.002--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypervolaemia02.05.04.019; 14.05.06.003---
Hypothyroidism05.02.03.001; 14.11.01.012--
Injection site reaction08.02.03.014; 12.07.03.015--
Intestinal obstruction07.13.01.002---
Intestinal stenosis07.13.01.003---
Nausea07.01.07.001--
Pancreatic pseudocyst07.18.03.002---
Pancreatitis acute07.18.01.002---
Pancreatitis chronic07.18.01.007---
Sleep disorder19.02.04.001---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Vomiting07.01.07.003--
Mental status changes19.07.01.001---
Intestinal polyp07.20.01.009; 16.05.01.002---
Gallbladder polyp09.03.02.003; 16.06.02.002---
Colorectal adenocarcinoma07.21.01.007; 16.13.01.009---
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
Appetite disorder14.03.01.004; 19.09.01.002---
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene